Ultragenyx Pharmaceutical Inc. (RARE): Price and Financial Metrics


Ultragenyx Pharmaceutical Inc. (RARE): $45.92

0.12 (+0.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RARE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

RARE POWR Grades


  • RARE scores best on the Sentiment dimension, with a Sentiment rank ahead of 73.15% of US stocks.
  • RARE's strongest trending metric is Stability; it's been moving up over the last 179 days.
  • RARE ranks lowest in Momentum; there it ranks in the 12th percentile.

RARE Stock Summary

  • For RARE, its debt to operating expenses ratio is greater than that reported by merely 10.7% of US equities we're observing.
  • RARE's price/sales ratio is 14.12; that's higher than the P/S ratio of 89.73% of US stocks.
  • Over the past twelve months, RARE has reported earnings growth of 144.38%, putting it ahead of 86.06% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Ultragenyx Pharmaceutical Inc are FDMT, SLDB, MTEM, RGNX, and SRRK.
  • Visit RARE's SEC page to see the company's official filings. To visit the company's web site, go to www.ultragenyx.com.

RARE Valuation Summary

  • In comparison to the median Healthcare stock, RARE's EV/EBIT ratio is 161.43% lower, now standing at -18.
  • RARE's price/earnings ratio has moved up 5 over the prior 92 months.
  • Over the past 92 months, RARE's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for RARE.

Stock Date P/S P/B P/E EV/EBIT
RARE 2021-08-31 18.2 6.7 -18.6 -18.0
RARE 2021-08-30 18.1 6.7 -18.5 -17.9
RARE 2021-08-27 17.7 6.6 -18.1 -17.5
RARE 2021-08-26 17.0 6.3 -17.4 -16.7
RARE 2021-08-25 17.0 6.3 -17.4 -16.8
RARE 2021-08-24 16.5 6.1 -16.9 -16.2

RARE Growth Metrics

    Its year over year cash and equivalents growth rate is now at 28.71%.
  • The year over year net income to common stockholders growth rate now stands at 52.07%.
  • Its 4 year net cashflow from operations growth rate is now at -158.8%.
Over the past 15 months, RARE's revenue has gone up $136,325,000.

The table below shows RARE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 351.406 -338.695 -454.025
2021-09-30 359.559 -346.803 -355.578
2021-06-30 359.382 -349.121 -351.425
2021-03-31 334.116 -196.414 -203.682
2020-12-31 271.03 -132.22 -186.566
2020-09-30 215.081 -141.807 -256.36

RARE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RARE has a Quality Grade of D, ranking ahead of 11.33% of graded US stocks.
  • RARE's asset turnover comes in at 0.234 -- ranking 185th of 681 Pharmaceutical Products stocks.
  • ADMS, AVDL, and QGEN are the stocks whose asset turnover ratios are most correlated with RARE.

The table below shows RARE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.234 0.955 -0.414
2021-03-31 0.225 0.956 -0.267
2020-12-31 0.194 0.977 -0.277
2020-09-30 0.174 0.973 -0.420
2020-06-30 0.140 0.962 -0.540
2020-03-30 0.116 0.959 -0.769

RARE Price Target

For more insight on analysts targets of RARE, see our RARE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $143.67 Average Broker Recommendation 1.58 (Moderate Buy)

RARE Stock Price Chart Interactive Chart >

Price chart for RARE

RARE Price/Volume Stats

Current price $45.92 52-week high $105.99
Prev. close $45.80 52-week low $45.20
Day low $45.20 Volume 462,900
Day high $46.70 Avg. volume 474,494
50-day MA $67.67 Dividend yield N/A
200-day MA $77.17 Market Cap 3.21B

Ultragenyx Pharmaceutical Inc. (RARE) Company Bio


Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company was founded in 2010 and is based in Novato, California.


RARE Latest News Stream


Event/Time News Detail
Loading, please wait...

RARE Latest Social Stream


Loading social stream, please wait...

View Full RARE Social Stream

Latest RARE News From Around the Web

Below are the latest news stories about Ultragenyx Pharmaceutical Inc that investors may wish to consider to help them evaluate RARE as an investment opportunity.

Analysts Predict Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) To Reach $186.00 In 12 Months

In last trading session, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) saw 0.35 million shares changing hands with its beta currently measuring 1.69. Company’s recent per share price level of $67.45 trading at -$0.37 or -0.55% at ring of the bell on the day assigns it a market valuation of $4.72B. That closing price of RARE’s stock is … Analysts Predict Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) To Reach $186.00 In 12 Months Read More »

Marketing Sentinel | February 26, 2022

J.P. Morgan Says Buy These 2 Stocks as They Are Oversold

2022 has started out with a marked increase in market volatility, accompanied by a sharp reversal of last year’s bullish trend. The sudden correction, and the shift to a more downbeat investor sentiment, are generally attributed to a series of increased risk factors. On the international front, these tensions include geopolitical tensions on the Russia-Ukraine border and around China’s belligerence. Domestically, factors impacting the markets include the inflation that is both high and rising; a

Yahoo | February 17, 2022

Ultragenyx Pharmaceutical Inc. 2021 Q4 - Results - Earnings Call Presentation

No summary available.

Seeking Alpha | February 11, 2022

Ultragenyx's (RARE) Q4 Earnings & Revenues Miss Estimates

Ultragenyx (RARE) reports wider-than-expected loss in the fourth quarter of 2021 while revenues miss estimates.

Yahoo | February 11, 2022

Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 10, 2022

Read More 'RARE' Stories Here

RARE Price Returns

1-mo -35.09%
3-mo -31.92%
6-mo -39.97%
1-year -55.37%
3-year -19.69%
5-year -17.87%
YTD -45.39%
2021 -39.25%
2020 224.12%
2019 -1.77%
2018 -6.25%
2017 -34.03%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.646 seconds.